Novel tools for measuring typhoid vaccine impact

Active Project Grant Awarded Last action

Award ID
R01AI181283
Recipient
Awarding agency
Obligated
$4,243,530

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 51% complete
Place of performance
Palo Alto, CA 94304, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Typhoid fever is a leading cause of invasive bacterial illness and death worldwide, with the majority of infections occurring in low- and middle-income countries where water and sanitation infrastructure is poor. Highly antimicrobial-resistant strains of salmonella typhi have been emerging and spreading internationally and intercontinentally, posing the risk of rising morbidity among reduced effectiveness of therapy. New typhoid conjugate vaccines have demonstrated a high level of effectiveness and are recommended by the who; however, many countries lack data on typhoid incidence, as the only reliable tool for typhoid diagnosis-blood culture-is not widely available in many resource-constrained settings where typhoid risk may be greatest. To address these gaps, we propose to leverage a large, cluster-randomized trial of a typhoid conjugate vaccine being performed in vellore, india, to test three emerging tools to measure community burden of typhoid: 1) seroepidemiological models, utilizing recently characterized seroresponses to s. Typhi antigens; 2) detection of s. Typhi-specific bacteriophages in wastewater, using low-cost assays; 3) phylodynamic methods that track measures of transmission intensity. This project will provide rigorous testing of multiple innovative methods amid uniquely intensive clinical surveillance in a vaccine trial. Overall, this project will address a critical need for public health tools to make typhoid surveillance scalable in resource-constrained settings, to inform vaccine introductions and monitor their impact.

Transactions

Action Obligated Date
Amendment $97,114
Amendment $641,757
Amendment $641,757
Amendment $667,635
Amendment $72,868
Amendment $72,868
Amendment $683,177
Amendment $683,177
Original award $683,177

Subawards

Subrecipient Amount Awarded
University Of California, Davis Novel tools for measuring typhoid vaccine impact $16,364
The General Hospital Corporation $259,888
University Of California, Davis $16,364
The Christian Medical College Vellore Association Dr John will oversee the study at Vellore where participants residing the study area will be consented and recruited to the serosurvey and environmental samples… $275,748
The General Hospital Corporation Novel tools for measuring typhoid vaccine impact $296,984
The Christian Medical College Vellore Association Dr John will oversee the study at Vellore where participants residing the study area will be consented and recruited to the serosurvey and environmental samples… $183,822

Quick answers

Who received award R01AI181283?

R01AI181283 was awarded to The Leland Stanford Junior University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 1, 2024.

How much is award R01AI181283 worth?

$4,243,530 has been obligated on R01AI181283.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login